ORXOY
Orexo AB

Orexo develops improved pharmaceuticals by combining well-known and well-documented substances with in- house innovative drug delivery technologies. Since Orexo was founded in 1995, four pharmaceutical products have been developed; Diabact® for diagnosing of the gastric ulcer bacterium helicobacter pylori,¹ Abstral® for breakthrough cancer pain, Edluar® for insomnia and Zubsolv® for opioid use disorder (OUD). The last three mentioned are built on the first-generation drug delivery platform – the sub lingual. Thanks to successful partnerships, these products have been approved in multiple markets and helped patients benefit from improved drugs worldwide. Orexo’s next-generation drug delivery platform, AmorphOX®, has unique properties for the development of differentiated pharmaceuticals that need to be absorbed rapidly by the body and remain stable over time. The technology can be applied to a broad scope of active substances and is the backbone of the development of clinical stage rescue medications and multiple early-stage projects. For pharmaceuticals that go beyond Orexo’s key therapeutic areas, the company intends to initiate development and commercialization partnerships. (1) Diabact was divested at the time of the sale of the subsidiary Kibion in 2015

Orexo outsource all activities related to packaging, manufacturing and supply of raw materials. Orexo has adopted a Code of Conduct for Suppliers that clarifies expectations and minimum requirements for suppliers, including legal compliance, human rights, business ethics, safety, health and environmental impact. Orexo’s ambition is to introduce these values throughout the supply chain to ensure that the high expectations of the company are met all over the world. In order to monitor and improve compliance with the supplier code, processes and approaches have been established that aim to ensure that risks regarding patient safety, product quality and a number of sustainability aspects are within an acceptable range. These processes and approaches also ensure that applicable commercial aspects, such as supply chain security, financial stability and other commercial risks in the supply chain are adequately investigated.